Zealthy sells access to care through several payment arrangements. A membership with a separate prescription bill is different from its Doctor + GLP-1 bundle, and neither should be reduced to the lowest medication figure on a promotional page. This review puts the plan name beside the price and the cancellation condition.
We checked Zealthy’s public pricing pages, complete FAQ answers and policies on October 15, 2026, and reviewed the FDA’s dated warning letter. This update replaces our earlier medication-specific coverage. We did not enrol, submit an insurance claim, test a shipment or assess individual clinical results; the earlier numerical rating has been removed.
One promotional page shows two first-month membership prices
The pricing landing page displays a $39 starting membership and a $135 monthly renewal. Its FAQ on the same page instead says the introductory membership is $49, describing an $86 discount rather than the $96 headline discount. Both versions were present in the rendered public page. We cannot determine which would govern an individual checkout.
The standard membership and medication are separate costs. The page advertises compounded semaglutide as low as $151 per month and tirzepatide as low as $216 with a three-month purchase. Those are conditional medication figures, not complete month-to-month treatment totals. The page also discusses a temporary membership discount linked to a three-month medication supply; request the actual multi-month payment schedule rather than adding unrelated lowest prices.
The bundled option has a different bill
The semaglutide bundle page advertises $217 for the first month and $297 per month thereafter, including medical care and medication when prescribed. It also identifies an extra $100 monthly charge for certain higher-dose treatment. A general no-hidden-fees headline therefore does not establish one price for every prescription. This review does not recommend a dose or reproduce a titration schedule.
The weight-loss FAQ lists a tirzepatide bundle at $349 for the first month. Its linked tirzepatide offer page returned 404 during this check, so we did not establish that plan’s current renewal price from the linked offer. Confirm that it is available to you and obtain its later price before comparing it with the semaglutide bundle.
The advertised $25 branded-drug copay is another pathway, conditional on insurance. It does not replace the membership fee or guarantee coverage. A care team’s assistance with authorization is not an insurer’s approval.
The platform and treating practice are separate
The subscription policy identifies FitRX, LLC doing business as Zealthy and names a provider network including Bruno Health, P.A. and affiliated medical groups. Ask which professional entity and clinician will handle your treatment, which pharmacy would dispense and how a clinical concern reaches that team. This review did not audit professional licences or pharmacy operations.
The service describes online messaging and coaching. Those features do not establish a measured response time. The broader policy also permits charges for such items as diagnostic testing, missed appointments and delivery where applicable. Ask which of those apply to the particular plan rather than assuming every charge is included in a membership headline.
The refund pages do not make one consistent promise
The general returns page says consultation and membership charges are nonrefundable and prescription orders become final after a prescription is issued and filled by the partner pharmacy. The longer subscription policy repeats that pharmacy-filling threshold, but another section describes medication finality after shipping. These are different points in the order process.
The semaglutide bundle page, meanwhile, advertises a full 30-day satisfaction refund without questions, and its FAQ describes refunds when a person is medically ineligible. The central weight-loss FAQ also promises a refund after an ineligible clinical assessment for the bundled option. Those statements are broader than the general nonrefund language. Obtain written confirmation of the offer-specific exception and the last point at which an order can be stopped; we did not test or resolve a refund claim.
Cancel the renewal, and check the medication order separately
The subscription policy requires cancellation before renewal and generally denies a prorated refund for the current paid term. The FAQ directs members to their portal profile, then Manage membership and Manage plan. Keep the confirmation and identify the next charge it prevents. The policy describes a specific trial-billing correction where a cancellation at least 36 hours before trial end was nevertheless charged; that is not a universal 36-hour deadline for every subscription.
The FAQ says memberships cannot be paused, while medication shipments can be delayed separately. Delaying a shipment therefore should not be assumed to stop membership billing. Nor should cancellation of a future renewal be treated as a refund of medication already processed.
Clinical review, pharmacy work and transit are different clocks
The central FAQ describes one to two business days for a provider review, followed by a delivery estimate of five to nine business days after approval and pharmacy submission. Another answer describes two to seven business days of pharmacy processing followed by two-day transit, with a two-to-nine-day overall estimate after the treatment plan is finalized. The promotional pricing page separately advertises shipping in one to four days after prescription. These are company estimates with differing wording, not a verified delivery promise.
Ask which estimate applies to your plan, whether the pharmacy has accepted the prescription and when a carrier actually has the package. The FAQ says three-month orders typically arrive as three one-month vials in one shipment; that does not establish the packaging, storage instructions or timeline for a specific order.
What the FDA warning establishes
The FDA letter dated September 9, 2025 addresses FitRX, LLC doing business as Zealthy after an August 2025 review of its website. The agency said compounded-semaglutide marketing implied equivalence to an FDA-approved product and was false or misleading. We did not establish a subsequent resolution from the sources reviewed, and the letter should not be presented as a batch-quality test or a finding about every patient’s care.
FDA’s current explanation says compounded drugs are not FDA-approved. Ingredient overlap alone does not establish that a compounded preparation has the approval or evidence of a branded product. For another policy comparison, our Blue Haven Rx review examines early renewal and upfront multi-month charges. Our lab-testing questions guide helps identify separate testing costs and who reviews the results.
Sources and review method
Public documents checked 2026-10-15. Provider pages support attributed service and price descriptions; FDA material supplies regulatory context. We did not conduct a purchase, patient study or professional credential audit. This article has not received clinician review. Offers may change.